Literature DB >> 14705495

Pharmacology of oral chemotherapy agents.

Ann Birner1.   

Abstract

The abundance of orally formulated chemotherapy agents reflects the expanding role of oral chemotherapy in the care of patients with cancer. Many oral chemotherapy agents have been used for a number of years, and several have been developed recently. Newer agents include the prodrugs capecitabine and temozolomide, the retinoid bexarotene, the immunomodulatory agent thalidomide, the protein kinase inhibitor imatinib, and the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Each agent has unique pharmacologic properties, dosing, and side-effect profiles. This article reviews these agents from a pharmacology perspective.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14705495     DOI: 10.1188/03.CJON.S6.11-19

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  4 in total

1.  Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel.

Authors:  Susan Goodin; Niesha Griffith; Beth Chen; Karen Chuk; Mikael Daouphars; Christian Doreau; Rinku A Patel; Rowena Schwartz; Maria José Tamés; Robert Terkola; Barbara Vadnais; Debbie Wright; Klaus Meier
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

2.  The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.

Authors:  Rujun Li; Dongfang Tang; Jinshi Zhang; Jinding Wu; Ling Wang; Jun Dong
Journal:  J Neurooncol       Date:  2013-09-25       Impact factor: 4.130

3.  An unusual case of aplastic anemia caused by temozolomide.

Authors:  Gazi Comez; Alper Sevinc; Ozlem Nuray Sever; Taner Babacan; Ibrahim Sarı; Celalettin Camci
Journal:  Case Rep Med       Date:  2010-12-01

4.  Effect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapy.

Authors:  S Bordonaro; F Romano; E Lanteri; F Cappuccio; R Indorato; A Butera; A D'Angelo; F Ferraù; P Tralongo
Journal:  Patient Prefer Adherence       Date:  2014-06-25       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.